Canada Pediatric Vaccines Market, Doses, Immunization (Vaccinated), Cases & Forecast

April 2015 | 104 pages | ID: C757E81BAF3EN
Renub Research

Abstracts

Pediatric vaccines market continues to be the success story for the manufacturers of pediatric vaccines in Canada. The value of the Canada pediatric vaccines market is expected to be slightly less than US$ 2 Billion by 2020. Pneumococcal vaccines (PCV) and Varicella vaccines are the leading market share holder in Canada and together they contribute more than 50% of the total Pediatric vaccines market. Polio, Measles, Mumps & Rubella (MMR), Diphtheria, Tetanus & Pertussis (DTaP) cases have shown diminishing trends from the year 2001 till 2013.

On the contrary, in terms of Doses, Diphtheria, Tetanus & Pertussis(DTaP) and Pneumococcal vaccines (PCV) have the highest number of doses in 2014.Diphtheria, Tetanus & Pertussis(DTap) and Polio are the highly penetrated vaccines in Canada pediatric vaccines market in 2014. It is predicted that these two vaccines will bolster the usable pattern in Canada. Canada Pediatric vaccines are expected to remain highly active in the future, fueled by the encouragement and financing from Governments and other health organizations. Canada Pediatric vaccines market is driven by favorable demographics, growing public acceptance and product innovation.

This is Renub Research 7th edition report on Vaccines Market & 2nd edition on Pediatric Vaccines Sector. Report titled "Canada Pediatric Vaccines Market, Doses, Immunization (Vaccinated), Cases & Forecast” talks about the pediatric vaccines scenario in Canada. This report provides information on Eight (8) segments of Pediatric Vaccines Market, Pediatric Vaccines Doses, Pediatric Vaccines number of Children Being Vaccinated and Number of Cases in Canada. This report covers in detail all aspects of Past, Present and Future Scenario. The report also entails major factors driving the Pediatric Vaccines Market and Challenges of Canada Pediatric Vaccines Market.

8 Pediatric Vaccines Covered in this Report are as follows:

1. Measles, Mumps & Rubella (MMR) Vaccines
2. Haemophilus Influenzae Type B (HIB) Vaccines
3. Polio Vaccines
4. Diphtheria, Tetanus & Pertussis (DTaP) Vaccines
5. Pneumococcal Vaccines
6. Hepatitis B Pediatric Vaccines
7. Varicella / Chicken Pox Vaccines
8. Meningococcal C Conjugate (Men–C) Vaccines

All the Pediatric Vaccines in this Report have been studied from Four View Points:

• Number of Cases
• Number of Doses
• Number of Children Being Vaccinated
• Market Size for all 8 Pediatric Vaccines

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government websites, Trade Journals, White Papers, Government Agencies, Magazines, Newspapers, Trade Associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Contents

1. EXECUTIVE SUMMARY

2. CANADA – PEDIATRIC VACCINES MARKET & FORECAST

3. CANADA – PEDIATRIC VACCINES MARKET SHARE & FORECAST

4. CANADA – PEDIATRIC VACCINES CASES, DOSES, IMMUNIZATION COVERAGE, MARKET & FORECAST

4.1 Canada – Measles, Mumps & Rubella (MMR) Vaccines & Forecast
  4.1.1 Number of Measles, Mumps & Rubella (MMR) Cases
  4.1.2 Number of Measles, Mumps & Rubella (MMR) Vaccines Doses
  4.1.3 Measles, Mumps & Rubella (MMR) – Number of Children Being Vaccinated
  4.1.4 Market Size of Measles, Mumps & Rubella (MMR) Vaccines
4.2 Canada – Haemophilus Influenzae Type B (HIB) Vaccines & Forecast
  4.2.1 Number of Haemophilus Influenzae Type B (HIB) Vaccines Doses
  4.2.2 Haemophilus Influenzae Type B (HIB) – Number of Children Being Vaccinated
  4.2.3 Market Size of Haemophilus Influenzae Type B (HIB) Vaccines
4.3 Canada – Polio Vaccines & Forecast
  4.3.1 Number of Polio Cases
  4.3.2 Number of Polio Vaccines Doses
  4.3.3 Polio Vaccines – Number of Children Being Vaccinated
  4.3.4 Market Size of Polio Vaccines
4.4 Canada – Diphtheria, Tetanus & Pertussis (DTaP) Vaccines & Forecast
  4.4.1 Number of Diphtheria, Tetanus & Pertussis (DTaP) Cases
  4.4.2 Number of Diphtheria, Tetanus & Pertussis (DTaP) Vaccines Doses
  4.4.3 Diphtheria, Tetanus & Pertusis (DTaP) – Number of Children Being Vaccinated
  4.4.4 Market Size of Diphtheria, Tetanus & Pertussis (DTaP) Vaccines
4.5 Canada – Pneumococcal Vaccines & Forecast
  4.5.1 Number of Pneumococcal Vaccines Doses
  4.5.2 Pneumococcal – Number of Children Being Vaccinated
  4.5.3 Market Size of Pneumococcal Vaccines
4.6 Canada – Hepatitis B Pediatric Vaccines & Forecast
  4.6.1 Number of Hepatitis B Pediatric Vaccines Doses
  4.6.2 Hepatitis B Pediatric – Number of Children Being Vaccinated
  4.6.3 Market Size of Hepatitis B Pediatric Vaccines
4.7 Canada – Varicella / Chicken Pox Vaccines & Forecast
  4.7.1 Number of Varicella / Chicken Pox Vaccines Doses
  4.7.2 Varicella / Chicken Pox – Number of Children Being Vaccinated
  4.7.3 Market Size of Varicella / Chicken Pox Vaccines
4.8 Canada – Meningococcal C (Men–C) Vaccines & Forecast
  4.8.1 Number of Meningococcal C (Men–C) Vaccines Doses
  4.8.2 Meningococcal C (Men–C) – Number of Children Being Vaccinated
  4.8.3 Market Size of Meningococcal C (Men–C) Vaccines

5. GROWTH DRIVERS OF CANADA PEDIATRIC VACCINES MARKET

5.1 Immunization & Reduce Preventable Infectious Diseases
  5.1.1 Immunization — a Collective Protection
  5.1.2 Immunization in Public Health — Past & Present
  5.1.3 Immunization—a Shared Responsibility
5.2 The Vaccine Injury Compensation Program
5.3 Transforming of Vaccine Technologies
5.4 Continuous Focus on Effective Communication Strategies

6. CHALLENGES OF CANADA PEDIATRIC VACCINES MARKET

6.1 Impediment in Pediatric Vaccine Research & Development
6.2 Barriers to New Entrants in the Pediatric Vaccines Market
6.3 Hurdles to Optimal use of Licensed Vaccines
  6.3.1 Technical Obstacles
  6.3.2 Economic obstacles
  6.3.3 Cultural Obstacles
6.4 Complexity of Vaccine Development & Approval System Thwarts Product Development
  6.4.1 Legal Obstacles
  6.4.2 General Technical Barriers
  6.4.3 Economic Barriers
  6.4.4 Regulatory Barriers
6.5 Shortening the Timeline for Vaccine Development

List Of Figures

LIST OF FIGURES

Figure 2–1: Canada – Pediatric Vaccines Market (Million US$), 2010 – 2014
Figure 2–2: Canada – Forecast for Pediatric Vaccines Market (Million US$), 2015 – 2020
Figure 3–1: Canada – Pediatric Vaccines Market Share (Percent), 2010 – 2014
Figure 3–2: Canada – Forecast for Pediatric Vaccines Market Share (Percent), 2015 – 2020
Figure 4–1: Canada – Number of MMR Vaccines Doses (Million Doses), 2010 – 2014
Figure 4–2: Canada – Forecast for Number of MMR Vaccines Doses (Million Doses), 2015 – 2020
Figure 4–3: Canada – Number of Children Being Vaccinated with MMR Vaccines (Million), 2010 – 2014
Figure 4–4: United States – Forecast for Number of Children Being Vaccinated with MMR Vaccines (Million), 2015 – 2020
Figure 4–5: Canada – Measles, Mumps & Rubella (MMR) Vaccines Market (Million US$), 2010 – 2014
Figure 4–6: Canada – Forecast for Measles, Mumps & Rubella (MMR) Vaccines Market (Million US$), 2015 – 2020
Figure 4–7: Canada – Number of Doses of Haemophilus Influenzae Type B Vaccines (Million Doses), 2010 – 2014
Figure 4–8: Canada – Forecast for Number of Doses of Haemophilus Influenzae Type B Vaccines (Million Doses), 2015 – 2020
Figure 4–9: Canada – Number of Children Being Vaccinated with Haemophilus Influenzae Type B Vaccines (Million), 2010 – 2014
Figure 4–10: Canada – Forecast for Number of Children Being Vaccinated with Haemophilus Influenzae Type B Vaccines (Million), 2015 – 2020
Figure 4–11: Canada – Haemophilus Influenzae Type B (HIB) Vaccines Market (Million US$), 2010 – 2014
Figure 4–12: Canada – Forecast for Haemophilus Influenzae Type B (HIB) Vaccines Market (Million US$), 2015 – 2020
Figure 4–13: Canada – Number of Doses of Polio Vaccines (Million Doses), 2010 – 2014
Figure 4–14: Canada – Forecast for Number of Doses of Polio Vaccines (Million Doses), 2015 – 2020
Figure 4–15: Canada – Number of Children Being Vaccinated with Polio Vaccines (Million), 2010 – 2014
Figure 4–16: Canada – Forecast for Number of Children Being Vaccinated with Polio Vaccines (Million), 2015 – 2020
Figure 4–17: Canada – Polio Vaccines Market (Million US$), 2010 – 2014
Figure 4–18: Canada – Forecast for Polio Vaccines Market (Million US$), 2015 – 2020
Figure 4–19: Canada – Number of Doses of DTaP Vaccines (Million Doses), 2010 – 2014
Figure 4–20: Canada – Forecast for Number of Doses of DTaP Vaccines (Million Doses), 2015 – 2020
Figure 4–21: Canada – Number of Children Being Vaccinated with DTaP Vaccines (Million Doses), 2010 – 2014
Figure 4–22: Canada – Forecast for Number of Children Being Vaccinated with DTap Vaccines (Million Doses), 2015 – 2020
Figure 4–23: Canada – Diphtheria, Tetanus & Pertussis (DTaP) Vaccines Market (Million US$), 2010 – 2014
Figure 4–24: Canada – Forecast for Diphtheria, Tetanus & Pertussis (DTaP) Vaccines Market (Million US$), 2015 – 2020
Figure 4–25: Canada – Number of Doses of Pneumococcal Vaccines (Million Doses), 2010 – 2014
Figure 4–26: Canada – Forecast for Number of Doses of Pneumococcal Vaccines (Million Doses), 2015 – 2020
Figure 4–27: Canada – Number of Children Being Vaccinated with Pneumococcal Vaccines (Million), 2010 – 2014
Figure 4–28: Canada – Forecast for Number of Children Being Vaccinated with Pneumococcal Vaccines (Million), 2015 – 2020
Figure 4–29: Canada – Pneumococcal Vaccines Market (Million US$), 2010 – 2014
Figure 4–30: Canada – Forecast for Pneumococcal Vaccines Market (Million US$), 2015 – 2020
Figure 4–31: Canada – Number of Doses of Hepatitis B Pediatric Vaccines (Million Doses), 2010 – 2014
Figure 4–32: Canada – Forecast for Number of Doses of Hepatitis B Pediatric Vaccines (Million Doses), 2015 – 2020
Figure 4–33: Canada – Number of Children Being Vaccinated with Hepatitis B Pediatric Vaccines (Million), 2010 – 2014
Figure 4–34: Canada – Forecast for Number of Children Being Vaccinated with Hepatitis B Pediatric Vaccines (Million), 2015 – 2020
Figure 4–35: Canada – Hepatitis B Pediatric Vaccines Market (Million US$), 2010 – 2014
Figure 4–36: Canada – Forecast for Hepatitis B Pediatric Vaccines Market (Million US$), 2015 – 2020
Figure 4–37: Canada – Number of Doses of Varicella Vaccines (Million Doses), 2010 – 2014
Figure 4–38: Canada – Forecast for Number of Doses of Varicella Vaccines (Million Doses), 2015 – 2020
Figure 4–39: Canada – Number of Children Being Vaccinated with Varicella Vaccines (Million), 2010 – 2014
Figure 4–40: Canada – Forecast for Number of Children Being Vaccinated with Varicella Vaccines (Million), 2015 – 2020
Figure 4–41: Canada – Varicella Vaccines Market (Million US$), 2010 – 2014
Figure 4–42: Canada – Forecast for Varicella Vaccines Market (Million US$), 2015 – 2020
Figure 4–43: Canada – Number of Doses of Meningococcal C (Men–C) Vaccines (Million Doses), 2010 – 2014
Figure 4–44: Canada – Forecast for Number of Doses of Meningococcal C (Men–C) Vaccines (Million Doses), 2015 – 2020
Figure 4–45: Canada – Number of Children Being Vaccinated with Meningococcal C (Men–C) Vaccines (Million), 2010 – 2014
Figure 4–46: Canada – Forecast for Number of Children Being Vaccinated with Meningococcal C (Men–C) Vaccines (Million), 2015 – 2020
Figure 4–47: Canada – Meningococcal C (Men–C) Vaccines Market (Million US$), 2010 – 2014
Figure 4–48: Canada – Forecast for Meningococcal C (Men–C) Vaccines Market (Million US$), 2015 – 2020

List Of Tables

LIST OF TABLES

Table 4–1: Canada – Number of Measles Cases (Number), 1999 – 2013
Table 4–2: Canada – Number of Mumps Cases (Number), 1999 – 2013
Table 4–3: Canada – Number of Rubella Cases (Number), 1999 – 2013
Table 4–4: Canada – Number of Polio Cases (Number), 2001 – 2013
Table 4–5: Canada – Number of Diphtheria Cases (Number), 1999 – 2013
Table 4–6: Canada – Number of nTetanus Cases (Number), 1999 – 2013
Table 4–7: Canada – Number of tTetanus Cases (Number), 1999 – 2013
Table 4–8: Canada – Number of Pertussis Cases (Number), 1999 – 2013
Table 5–1: Canada – Incidence of Selected Vaccine–preventable Disease, Pre–vaccine era compared with Pre-Vaccine Era to 2013
Table 5–2: Improvement Strategies or Requirements – the Joint Commission and the Project’s Collaborating Organizations